Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: quetiapine fumarate (Seroquel) Clear all
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

NCT00326105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • El Centro, California • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 4 Interventional

Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

NCT00043849
View directory record Official record
Conditions
Dementia, Parkinson Disease
Interventions
Quetiapine
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 12, 2026, 3:05 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 12, 2026, 3:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

SGA-induced Metabolic Syndrome in Bipolar Youth

NCT01858948
View directory record Official record
Conditions
Bipolar Youth Treated With Second-generation Antipsychotics
Interventions
Omega, Placebo, Quetiapine fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

NCT01971203
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
seroquel xr, CBT
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional Results available

Trial of Quetiapine in Anorexia Nervosa

NCT00518973
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Quetiapine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Bipolar Depression

NCT00811473
View directory record Official record
Conditions
Bipolar Depression
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 4 Interventional

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCT00208819
View directory record Official record
Conditions
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
Interventions
risperidone, quetiapine, olanzapine, divalproex
Drug
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 12, 2026, 3:05 PM EDT
Not listed Phase 1 Interventional

Interaction Between Cocaine and Quetiapine - 1

NCT00087750
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Quetiapine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional

CATIE-Alzheimer's Disease Trial

NCT00015548
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Olanzapine, Quetiapine, Risperidone, Citalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
34
States / cities
Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 4 Interventional Results available

Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

NCT00186043
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Quetiapine/Seroquel, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
Interventions
quetiapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 12, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 12, 2026, 3:05 PM EDT
Terminated Early Phase 1 Interventional

Methamphetamine-Quetiapine Interactions in Humans

NCT00567866
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Quetiapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 12, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 12, 2026, 3:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171
View directory record Official record
Conditions
Delirium
Interventions
quetiapine, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

NCT00550147
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Oros Methylphenidate, quetiapine
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 12, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Quetiapine & Placebo, Lithium and Placebo, Healthy Controls
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 12, 2026, 3:05 PM EDT